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 Abstract – A targeted, stimuli-responsive, polymeric drug 
delivery vehicle has been developed to help alleviate the severe 
side-effects caused by narrow therapeutic window drugs.  
Doxorubicin, a commonly used chemotherapeutic agent has 
been conjugated to dextran by two different techniques.  In 
the first method, doxorubicin and hepatocyte-targeting 
galactosamine were attached to dextran through amine bonds.  
Conjugation efficiency based on the amount loaded of each 
reactant varied from 1% to 50% for doxorubicin and from 
2% to 20% for galactosamine, depending on various synthesis 
parameters.  For the second conjugate, doxorubicin was 
attached to dextran through an acid-labile hydrazide bond.  
Fluorescence quenching indicated that all our conjugates can 
bind to DNA.  The degree of binding was improved with 
increasing polymer molecular weight and substitution of 
doxorubicin, and also with hydrazide-bonded conjugate.  In 
cell culture experiments, we have found that the uptake of 
conjugates was much lower than that of free doxorubicin.  
Lower uptake of conjugates decreased the toxicity of 
doxorubicin.  Also, the uptake of non-galactosylated conjugate 
was lower than that of the galactosylated conjugate.  
Microscopy studies indicated that doxorubicin was localized 
almost exclusively at the nucleus, whereas the amine-bonded 
conjugates were present throughout the cell.  Targeted amine-
linked conjugates and hydrazide-bonded conjugates achieved 
greatly improved cytotoxicity.  Following uptake, the 
doxorubicin was dissociated from the hydrazide conjugate in 
an endosomal compartment and diffused to the nucleus.  The 
LC50 values of non-targeted amine-linked, targeted amine-
linked, and hydrazide-linked doxorubicin were 19.81 µg/mL, 
7.33 µg/mL and 4.39 µg/mL, respectively.  The amine-linked 
conjugates were also tested on a multidrug-resistant cell line; 
the LC50 values of doxorubicin and the non-targeted amine-
linked conjugate were 8.60 µg/mL and 36.02 µg/mL, 
respectively.  
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I. INTRODUCTION 
ancer is one of the leading causes of death.  Current 
treatment involves various combinations of surgery, 
radiation therapy and chemotherapy.  Chemotherapeutic 
agents are cytotoxic drugs, which affect any cells in the 
body that are actively dividing.  Therefore, in addition to 
cancerous cells, they affect bone marrow, causing a 
suppression of the immune system, loss of hair and skin 
cells, etc.  Furthermore, they can cause long-term damage 
to major organs in the body.  To avoid these serious side-
effects, conventional chemotherapeutic agents must be 
administered at a suboptimal dose, which is insufficient to 
treat the cancer satisfactorily in one dosage.  Physicians 
have attempted to treat cancer using these lower doses over 
a longer period of time, however, this has also proven 
ineffective due to the development of drug resistance by 
the cancerous cells [1].  
 These challenges can be tackled by targeted drug 
delivery, which increases the range in which a drug is both 
safe and effective.  Targeted delivery can be achieved by 
two approaches: site-specific transport and site-specific 
activation.  Site-specific transport is attained when an 
active drug is preferentially concentrated at the target site, 
such as can be achieved with an implant or transdermal 
drug delivery.  Site-specific activation or stimuli-
responsive delivery is accomplished when a drug is 
activated by a controlled mechanism at or near the target 
site [2]. 
 The least invasive and most promising method of targeted 
drug delivery is protein targeted delivery.  Protein 
targeting, specifically, lectin (carbohydrate receptor) 
mediated targeting, holds potential due to high specificity 
and affinity, rapid internalization by receptor-mediated 
endocytosis, and relative ease of processing [2–4]. 
 Much research has been performed in the area of protein 
targeted delivery in the last two decades.  Crews et al. have 
used a number of different antibodies to target human 
breast cancer cell lines to improve cytotoxicity of the drugs 
[5].  Monsigny et al. have shown that murine leukemia 
cells express a high concentration of L-fucose (a modified 
monosaccharide) receptors [6], and are studying the use of 
glycoconjugates for gene delivery.  Yamazaki et al. are 
using glycoprotein-liposome conjugates for drug delivery 
[7].  In spite of the significant progress in this field, more 
work is needed in improving target recognition, minimizing 
premature release, and preserving drug efficacy regardless 
of chemical alteration [8–10]. 
C
 Polymeric drug delivery vehicles can enhance the 
performance of a drug in several ways.  They increase the 
circulation time in the body, protect the drug from various 
enzymes and decrease non-specific toxicity [8].  Also, 
chemical modification of polymers allows addition of 
functionalities, such as receptor targeting and stimuli-
responsive activation of the drug.  Another advantage is 
that polymer-bound drugs are less likely to be expelled 
from multidrug-resistant cells [9].  Conversely, conjugation 
to a polymer results in reduced therapeutic effect, 
compared to the free drug.  Hence, release of the drug after 
delivery to the target or site-specific activation is desirable.  
A number of intracellular vesicles such as endosomes and 
lysosomes are maintained at low pH, and incorporating an 
acid-labile bond between the polymer and drug would 
allow for activation after delivery.  
 The purpose of our project is to synthesize a targeted, 
pH-sensitive, polymeric drug delivery vehicle to deliver 
doxorubicin for cancer chemotherapy to hepatocytes.  
Doxorubicin is most commonly used in the treatment of 
lymphoma, osteosarcoma and other sarcomas, carcinomas, 
and melanoma.  In this paper, we describe the synthesis of 
two dextran-doxorubicin conjugates.  The amine-linked 
dextran-doxorubicin-galactose (DDG) conjugate expresses 
galactose, and preferentially transports doxorubicin to 
hepatocytes, which express a high surface density of 
galactose receptors.  The dextran-hydrazide-doxorubicin 
(DHD) conjugate contains a pH-sensitive hydrazide bond 
between dextran and doxorubicin, and releases the drug in 
the endosome at a low pH.  
II. EXPERIMENTAL 
A. Synthesis of Amine-Linked Dextran-Doxorubicin-
Galactose Conjugate 
 The hydroxyl groups on dextran were activated by 
stirring 1 g of dextran in 100 mL of 0.03 M NaIO4 
overnight [11].  The activated polyaldehyde dextran (PAD) 
was purified by dialysis against deionized water for three 
days, and recovered by lyophilization.  PAD reacted with 
the primary amines on doxorubicin and galactosamine to 
form an unstable imine bond, which could be reduced with 
sodium borohydride to form a stable amine bond.  PAD 
(100 mg) was dissolved in 5 mL of phosphate buffer 
solution (PBS) (pH 7.4), reacted with doxorubicin and 
galactosamine, and subsequently reduced with NaBH4 at 
37°C for 2 h.  The resulting DDG conjugates were dialyzed 
against deionized water and lyophilized.  The loadings of 
doxorubicin and galactose on the conjugates were 
determined by absorbance at 485 nm and elemental 
analysis, respectively. 
 
B. Synthesis of Acid-Labile Dextran-Hydrazide-
Doxorubicin Conjugate 
 The synthesis of acid-labile DHD conjugates was adapted 
from work by Ramirez [12] and Etrych [13].  All chemicals 
in this synthesis were dried under vacuum overnight; the 
reaction was also carried out under vacuum.  One gram of 
dextran was dissolved in 100 mL of a solution of 20 g/L of 
LiCl in dimethyl formamide at 90°C.  The mixture was 
then transferred to an ice bath, and 1.5 mL of pyridine and 
3.7 g of 4-nitrophenylchloroformate were added.  The 
reaction mixture was kept in an ice bath for 4 h, and the 
resulting nitrophenyl carbonate-dextran (Dex-ONP) 
precipitated in a 4:1 mixture of ethanol and diethyl ether.  
Dex-ONP was centrifuged, washed two more times with 
ethanol/diethyl ether, and dried under vacuum.  The 
presence of the nitrophenyl group on dextran was 
confirmed by nuclear magnetic resonance (NMR) and 
photoacoustic Fourier-transform infrared (PA-FTIR) 
spectroscopies. 
 One gram of the synthesized Dex-ONP was dissolved in 
25 mL of dimethyl sulfoxide, and reacted with a ten-fold 
excess of hydrazine.  The reaction was allowed to proceed 
for 3 h, and then dialyzed against deionized water for 2 
days.  The product, Dex-hydrazide was recovered by 
lyophilization.  
 In the final step, 100 mg of Dex-hydrazide was dissolved 
in 5 mL of PBS at a pH of 7.4.  Doxorubicin (8 mg) and 1 
drop of glacial acetic acid were added, and allowed to react 
for 48 h.  The final polymer conjugate was dialyzed against 
PBS (pH 7.4) and freeze dried.  The degree of substitution 
of doxorubicin was determined using absorbance of 
doxorubicin at 485 nm.  
 
C. Cell-Free Efficacy of Polymer Conjugates 
 Doxorubicin intercalates with DNA in the nuclei of cells.  
This interferes with cell division, and eventually leads to 
cell death.  Binding with DNA causes fluorescence 
quenching of doxorubicin, and allows a fluorescence-based 
cell-free assay to evaluate the efficacy of the polymer 
conjugates [14].  Fluorescence was measured (ex. 488 
nm/em. 590 nm) for a uniform amount of doxorubicin or 
conjugate in the presence of increasing concentrations of 
calf thymus (ct)-DNA.  
 
D. Cell-Free Release from Acid-Labile Conjugates 
 The release of doxorubicin from the acid-labile DHD 
conjugate was tested in 0.1 M of sodium acetate buffer 
with 0.05 M of sodium chloride at pH 7.4 and 5.0 [13].  
The DHD conjugate was dissolved in PBS (pH 7.4), 
transferred to a Macro Fast DispoDialyzer cassette 
(Harvard Apparatus) and immersed in 5 mL of buffer at 
each pH.  At each time point, 0.75 mL of sample was 
removed for analysis, and replaced with fresh buffer. 
Release was observed over a 24-h period.  The 
concentration of doxorubicin in the buffer was determined 
by absorbance at 485 nm.  
 
E. In Vitro Efficacy of Polymer Conjugates 
 Hepatocytic cell lines were used to test uptake of 
galactosylated conjugates since hepatocytes are known to 
express a high surface concentration of galactose binding 
sites.  The BNL CL.2 cell line (murine hepatocytes) was 
purchased from ATCC, and cultured in Dulbecco’s 
Minimum Essential Medium supplemented with 10% FBS 
and 1% Penicillin-Streptomycin (ATCC) at 37°C in a 5% 
CO2 atmosphere.  
 For cytotoxicity studies, the cells were plated at 400/mm2 
in six-well plates, and allowed to adhere for 12–18 h.  The 
medium was then replaced with complete medium 
containing doxorubicin or conjugates, and incubated for up 
to 24 h.  All experiments were performed in triplicates.  
Cells were harvested with 0.25% Trypsin/0.53 mM of 
ethylenediaminetetraacetic acid (ATCC), and the relative 
uptake of doxorubicin or conjugate was evaluated using 
flow cytometry (Becton Dickinson FACScan, FL-2).  To 
determine the killing efficiency, harvested cells were 
replated in 96-well plates (n = 6), and allowed to adhere 
overnight.  The medium was replaced with 100 µL of fresh 
medium and 10 µL of the MTT reagent [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], 
and the plate was incubated for 2 h.  The MTT reagent 
reacted in the mitochondria of living cells to produce a 
purple precipitate.  One hundred microliters of the 
detergent were then added, and the cells were incubated for 
another 3 h.  The absorbance at 570 nm was measured 
when all the precipitate had dissolved.  
 Hep G2, a human hepatocyte cell line was also used to 
test the amine-linked conjugates.  Hep G2 cells contain the 
multidrug-resistant protein, which is a membrane 
transporter that expels a wide range of exogenous toxins 
from the cell [15].  Due to this, Hep G2 cells have a 
resistance to several chemotherapeutic agents including 
doxorubicin.  However, it is more difficult for the cells to 
expel a drug if it is polymer-bound instead of free.  Hep G2 
cells were grown in Eagles’ Minimum Essential Medium 
supplemented with 10% FBS and 1% Penicillin-
Streptomycin.  Cell culture and the cytotoxicity 
experiments were carried out as described for the BNL 
CL.2 cell line.  
 The concentration at which 50% cell death occurred 
(LC50) was determined from the slope and intercept of the 
straight line obtained by inverting the dose vs. cell death 
data from the cytotoxicity studies.   
 Microscopy studies were conducted in chamber slides 
using 2 µg/mL of nominal doxorubicin concentration at 4, 
8 and 24 h.  Cells were fixed with 1% paraformaldehyde 
solution in PBS for 1 h, followed by 2% paraformaldehyde 
for 30 min.  In some experiments, the nuclei of cells were 
counterstained with SYBR-Green (Molecular Probes) for 5 
min after fixing the cells.  Images were taken with a Zeiss 
LSM confocal microscope.  
III. RESULTS AND DISCUSSION 
A. Synthesis and Characterization of Polymer Conjugates 
1) Amine-Linked DDG Conjugate 
 The degree of substitution of doxorubicin varied from 1% 
to 5%, and that of galactose varied from 5% to 15%.  Fig. 1 
shows the degree of substitution of galactosamine and 
doxorubicin for a number of different conjugates.  The 
mass of doxorubicin was kept constant, while increasing 
the mass of galactosamine.  Conjugation efficiency based 
on the amount loaded of each reactant varied from 3% to 
20% for doxorubicin and from 2% to 20% for 
galactosamine.  
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Fig. 1.  Effect of varying the mass of galactosamine added on 
the degrees of substitution (DS) of doxorubicin and galactose 
for the DDG conjugate.  Mass of doxorubicin was kept 
constant at 20 mg.  
 
 As shown in Fig. 1, the degree of substitution of 
galactosamine could be controlled by varying the amount 
of galactosamine loaded into the reaction vessel.  However, 
the degree of substitution of doxorubicin decreased with an 
increased loading of galactosamine.  Both doxorubicin and 
galactosamine reacted with PAD by the same mechanism; 
therefore, adding excess galactosamine would lower the 
degree of substitution of doxorubicin.  Increasing the mass 
of doxorubicin would help improve the degree of 
substitution of doxorubicin (see Fig. 2).  The reaction was 
also carried out over two days: PAD was first reacted with 
doxorubicin and subsequently with galactosamine.  This 
increased the substitution efficiency significantly. 
 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0 50 100 150 200 250
Mass of Galactosamine Added (mg)
D
S 
of
 D
ox
 (%
)
0
2
4
6
8
10
12
14
16
D
S
 o
f G
al
 (%
)
20 mg
60 mg
40 mg
30 mg
  
Fig. 2.  Effect of varying the masses of galactosamine and 
doxorubicin added on the degrees of substitution (DS) of 
doxorubicin and galactose for the DDG conjugate.  The mass 
of doxorubicin added was marked for each point. 
   
2) Acid-Labile DHD Conjugate 
 The structure of Dex-ONP was confirmed by 1H NMR 
and PA-FTIR (Figs. 3 and 4).  The glucosidic protons 
appeared on the NMR spectrum in several bands between 
3.5 and 5.5 ppm.  The peaks at 7.5 and 8.3 ppm 
corresponded to the phenyl protons on the 4-nitrophenyl 
carbonate group.  The acyclic carbonate on Dex-ONP 
showed a characteristic infrared peak at 1770 cm-1, which 
shifted to a lower wavenumber for Dex-hydrazide. 
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Fig. 3.  1H NMR spectra of dextran and Dex-ONP. 
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Fig. 4.  PA-FTIR spectra of dextran, Dex-ONP and Dex-
Hydrazide.  Carbonate peak at 1770 cm-1 was highlighted.   
 
 The effect of various synthesis parameters on the degree 
of substitution of doxorubicin was studied.  The amounts of 
4-nitrophenyl chloroformate, hydrazine and doxorubicin, as 
well as the molecular weight of the drug, were varied.  The 
optimum values of the three reactants that gave the 
maximum degree of substitution for doxorubicin were 
given in the synthesis protocol.  The amount of 
doxorubicin added was found to be the most important 
factor.  The degree of substitution also increased when 
polymers with higher molecular weights were used. 
 
 B. Cell-Free Testing 
1) DNA Binding 
DextranDextran  Fluorescence quenching indicated that all our conjugates 
were bound to DNA.  As shown in Fig. 5, amine-linked 
conjugates of various molecular weights and substitutions 
exhibited this effect, though not to the same extent as free 
doxorubicin.  The degree of binding increased with 
polymer molecular weight.  170kDa dextran-doxorubicin 
(DD) and DDG underwent almost complete quenching, 
whereas 10kDa and 40kDa samples only showed ~ 50% 
quenching.  A greater degree of substitution of doxorubicin 
also improved quenching (170kDa DD quenched slightly 
more than 170kDa DDG). 
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Fig. 5.  Fluorescence quenching of amine-linked conjugates.  
Molecular weights of polymers were indicated.  
 
 The acid-labile DHD conjugates showed a much greater 
degree of binding with ctDNA than the DD conjugate of 
similar molecular weights (Fig. 6).  The doxorubicin on the 
DDG conjugates was bound through the amine sugar group 
of doxorubicin, whereas for the acid-labile conjugate, the 
acetyl group was involved in the binding.  Frederick et al. 
have reported that though the major binding occurs at the 
chromophore site of doxorubicin, the amino sugar also 
extends into the minor groove of DNA to form a hydrogen 
bond [16].  Since the amine-linked conjugates were bound 
through the sugar group, the binding with DNA was 
weaker in nature.  This explained the significant difference 
in binding seen in Fig. 6.  
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Fig. 6.  Fluorescence quenching of acid-labile conjugate vs. 
amine-linked conjugate.  
   
2) pH-Responsive Release of Doxorubicin  
 Fig. 7 shows the pH-sensitive release of doxorubicin 
from DHD conjugates.  At the endosomal pH of 5, the rate 
of release was much greater than that at a physiological pH 
of 7.4, indicating that this material would release the active 
drug inside the endosome.  There was some release from 
the conjugate at pH 7.4 as well, though the percentage 
released was significantly less than that at pH 5.0.  
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Fig. 7.  Release of doxorubicin from DHD conjugate (MW 
10,000) in buffers of different pH’s.  
 
 C. Cell Culture Studies 
1) Doxorubicin Uptake 
 All cells have a basal level of fluorescence associated 
with them.  For the cytotoxicity studies, flow cytometry 
was used to determine the excess fluorescence of cells 
incubated with either doxorubicin or conjugates.  Fig. 8 
shows the ratio of the fluorescence of cells incubated with 
doxorubicin or conjugates to the fluorescence of control 
cells.  BNL CL.2 cells were incubated in increasing 
concentrations of various conjugates.  Figure 8 shows that 
the uptake of free doxorubicin was much higher than the 
uptake of the conjugates, which reached a plateau at a 
relatively low ratio.  Therefore, we would expect the 
conjugates to be less toxic than doxorubicin.  The DDG 
conjugate, which was targeted to hepatocytes by galactose, 
was taken up more than the non-targeted DD conjugate.  
The acid-labile DHD conjugate also experienced a higher 
uptake than the DD conjugate.  
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Fig. 8.  Doxorubicin-associated fluorescence of hepatocytes 
incubated with doxorubicin and conjugates.  
 
2) Cytotoxicity Studies on the BNL CL.2 Cell Line 
 Fig. 9 shows the dose response curve of doxorubicin and 
two conjugates.  The LC50 of several conjugates are listed 
in Table 1.  The amine-linked, non-targeted conjugate (DD) 
required 20 times the dose of free doxorubicin to achieve 
50% cell death (LC50 of 19.81 µg/mL compared to 0.97 
µg/mL).  It was much less toxic than free doxorubicin for a 
number of reasons.  There was less uptake of doxorubicin 
in the polymer-bound form as shown in Fig. 8.  
Furthermore, the polymer-conjugated doxorubicin that was 
taken up did not bind as strongly to DNA as free 
doxorubicin (Fig. 5).  
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Fig. 9.  Dose response curve of doxorubicin and polymer 
conjugates in BNL CL.2 cells. 
 
 Conjugates that were targeted to hepatocytes with 
galactose were significantly more toxic than the non-
targeted DD conjugate.  The LC50 values of two different 
types of targeted conjugates were shown in Table 1.  The 
toxicity of the DDG conjugates increased with an increase 
in the degree of galactose substitution from 3.69% to 
5.62%. 
 
TABLE 1 
LC50 of Doxorubicin and Various Conjugates. 
Cell Line Conjugate LC50 (µg/mL) 
Doxorubicin 0.97 
DD 19.81 
DDG 3.69* 7.33 
DDG 5.62* 5.86 
BNL CL.2 
DHD 4.39 
Doxorubicin 8.60 Hep G2 
DD 36.02 
*Degree of substitution of galactose. 
 
 Fig. 10 shows the fluorescence micrographs of 
hepatocytes incubated with doxorubicin (left) and DDG 
5.62 (right) for 8 h.  The free doxorubicin was localized 
almost exclusively in the nuclei of cells.  In contrast, the 
polymer conjugate was found in the entire cell, with 
localization occurring mostly outside the nucleus.  This 
was another reason that the polymer conjugates were less 
toxic than the free doxorubicin.  
 For the pH-sensitive DHD conjugate, the LC50 was 4.39 
µg/mL, which was over 75% lower than that of the DD 
conjugate (Table 1), and comparable to the DDG 
conjugates. 
   
 
Fig. 10.  BNL CL.2 cells incubated with doxorubicin (left) and 
DDG 5.62 (MW 10,000) (right) for 8 h at a doxorubicin 
concentration of 2 µg/mL.  
 
 
Fig. 11.  BNL CL.2 cells incubated with DD (MW 10,000) 
(left) and DHD (MW 10,000) (right) for 4 h at a doxorubicin 
concentration of 2 µg/mL.  The nuclei were counterstained 
with SYBR Green. 
 
 Fig. 11 shows the confocal laser scanning microscopy 
images of BNL CL.2 cells incubated with DD (left) and 
DHD (right) with the nuclei counterstained with SYBR 
Green.  Yellow indicated the co-localization of doxorubicin 
(red) and nucleus (green).  This micrograph confirmed our 
previous observation that the amine-linked conjugates did 
not enter the nucleus.  It also showed that the doxorubicin 
on the DHD conjugates entered the nuclei efficiently, 
indicating that doxorubicin was released from the polymer 
in an intracellular vesicle.   
3) Cytotoxicity Studies on the Hep G2 Cell Line 
 Cytotoxicity studies were also carried out on Hep G2 
cells (Fig. 12), which are resistant to several drugs 
including doxorubicin.  The LC50 values for doxorubicin 
and a non-targeted amine-linked conjugate (DD) were 8.60 
µg/mL and 36.02 µg/mL, respectively.  In this case, only 
four times the loading of doxorubicin was required by DD 
for the same effect, compared to the 20 times higher 
doxorubicin loading required by DD for the non-resistant 
cell line (BNL CL.2). 
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Fig. 12.  Dose response curve of doxorubicin and amine-
linked conjugate (MW 170,000) in Hep G2 cells. 
  
IV. CONCLUSIONS 
 We have synthesized two conjugates with two different 
functionalities.  The dextran-doxorubicin-galactose (DDG) 
conjugate can successfully target hepatocytes.  The targeted 
conjugates are significantly more effective at inducing cell 
death than the control non-targeted conjugates.  The 
dextran-hydrazide-doxorubicin (DHD) conjugates released 
doxorubicin in the low pH endosomal compartments when 
taken up by the cells, and are also effective at inducing cell 
death. We are currently working on developing materials 
that would combine the two functionalities to further 
improve the drug delivery system.  
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